Recursion Pharmaceuticals - AI Stock Analysis

Analysis generated November 18, 2025

Recursion Pharmaceuticals is a clinical-stage biotechnology company that utilizes machine learning and high-throughput biology to accelerate its drug discovery processes. The company's platform, called the Recursion Operating System (Recursion OS), integrates biological science with machine learning and automation to enhance drug discovery and development. By merging data-rich biology with computational science, Recursion aims to identify novel drug candidates more efficiently and potentially bring treatments to market faster than traditional methods.

Fundamental Analysis

Revenue for the last quarter was $5.2 million. This represents a stark decrease of 72.91% compared to the previous quarter, signaling potential issues with growth. Comparing this quarter to the same quarter last year, there is a more significant decrease of 80.16%, which amplifies these concerns.

Net income for the last quarter stood at $162 million, reflecting an increase of 5.61% compared to the previous quarter—a positive sign of growth. However, when measured against the same quarter last year, net income decreased by 69.59%, a worrying trend that calls attention to recent profitability difficulties.

EBIDTA for the last quarter was $172 million, a decrease of 16.69% compared to the previous quarter. This figure is alarming not only because of the quarterly decline but primarily due to the staggering 95.85% reduction from the same quarter last year. Additionally, insider selling has been observed in recent months, which generally signals a bearish outlook.

Technical Analysis

Today's stock price is $4.19. This presents a decrease of 28.50% from a month ago, suggesting a worrying short-term trend. The price has decreased by 33.17% compared to a year ago, further signaling long-term concerns.

The trend appears to be bearish, with the current Simple Moving Average (SMA10) at $4.36 compared to the previous SMA10 of $4.40. This decrease indicates potential downward price movement. Additionally, the Relative Strength Index (RSI) is 63, indicating that the stock is in neutral condition. However, the RSI nearing 70 would suggest being overbought, and nearing 30 would indicate oversold conditions.

Alternative Data Analysis

Starting with job postings and employee sentiment at Recursion Pharmaceuticals: the company currently has 22 open positions, a number that has remained stable, reflecting a certain degree of stability. Employee sentiment, however, is low with only 44% of employees having a positive business outlook—down by 15% in recent months, adding to the concerns.

On the customer acquisition front, Recursion Pharmaceuticals has an estimated 35,000 visitors to their website. This is down by 38% in recent months, a concerning indicator as it may suggest a decline in customer interest. However, customer engagement on social media shows some promise; the company has 16,000 followers on their Twitter page, with follower count up by 5%, indicating increased public interest.

According to AltIndex's AI score—which utilizes a combination of fundamental, technical, and alternative data for prediction—Recursion Pharmaceuticals has a score of 42, suggesting a hold signal.

Conclusion

Based on the extensive data provided, Recursion Pharmaceuticals presents a mixed outlook. On the fundamental side, declines in revenue and EBITDA compared both quarterly and yearly are a cause for concern. Insider selling adds to the negative sentiment. Technical indicators exhibit a bearish trend with declining SMA and a neutral but cautious RSI.

Alternative data insights add another layer of caution: declining web traffic and low employee sentiment contrast the modest increase in social media engagement. The AltIndex AI score of 42 aligns with a hold position, suggesting that existing investors may want to maintain their shares but new investors should exercise caution.

Given this analysis, Recursion Pharmaceuticals might be best suited for a hold recommendation, where stakeholders would wait for more favorable trends and indicators before making further investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.